7 lectures · 152 items
11 min
11 min
9 min
6 min
5 min
15 min
6 min
Global guideline on the use of GLP-1 medicines in treating obesity issued by WHO
EU Launches Ambitious "Safe Hearts Plan": A New Roadmap in Cardiovascular Health
Introducing GPcardio: Bridging the Gap in Cardiovascular Care
Primary Prevention of Atherosclerotic Cardiovascular Disease (ASCVD) in Primary care: A Systematic Review of Guidelines
Enhanced remote medication program boosts GDMT prescriptions for high CV or kidney risk in T2D patients
Slides | Take home messages of EPCCS Guidance on 'Current management of diabetes and CV risk in primary care'
Slides: Managing diabetes in daily cardiovascular practice: A multidisciplinary approach
Slides: Targeting CVD in diabetes: novel strategies to tackle the risk
Slides: Type 2 Diabetes & CV outcomes: More than Glucose management? - lessons from GLP1-ra trialsEducation, exchange, guidance and interaction during EPCCS Summit 2019
Slides | Diabetes and cardiovascular risk
Slides | What's the evidence that diabetes is linked to CVD risk?Diabetes and cardiovascular risk
Current management of diabetes and cardiovascular risk in primary care 
Slides | Type 2 diabetes & cardiovascular disease updatea systematic review and meta-analysis.
A systematic review and meta-analysis demonstrates that finerenone significantly slows eGFR decline in patients with non-diabetic chronic kidney disease (difference in slope +0.70 mL/min/1.73m²/year…
In a prospective cohort study of 18,741 patients with type 2 diabetes on lipid-lowering therapy, elevated remnant cholesterol and hsCRP levels were each independently associated with a higher risk of…
upfront statin plus ezetimibe or statin alone first gives the same outcomes in vascular disease (8.5 versus 7.9 percent), as long as you titrate to the LDL target
Presented in LBS.03 at AHA 2026 (Saturday 7 November, Byeong-Keuk Kim, Severance Hospital, Yonsei University, Seoul) and published simultaneously in Circulation. In the 2 by 2 factorial Ez-PAVE trial…
A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
A meta-analysis of 85 randomized trials (70,543 participants) demonstrates that SGLT2 inhibitors produce a small but statistically significant increase in hemoglobin (+0.60 g/dl) and hematocrit…
Pooled Analysis of BROADWAY/BROOKLYN and an Updated Meta-analysis of CETP Inhibitor Trials.
A pooled analysis of phase 3 trials (BROADWAY/BROOKLYN) and an updated meta-analysis evaluated the impact of the CETP inhibitor obicetrapib on glycaemia and new-onset diabetes in 1,700 participants…
A Non-Steroidal Mineralocorticoid Receptor Antagonist and Its Emerging Role in Cardiovascular-Kidney-Metabolic Syndrome.
This narrative review synthesizes evidence for finerenone in cardiovascular-kidney-metabolic (CKM) syndrome, drawing on phase 3 trials including FIDELIO-DKD, FIGARO-DKD, FINEARTS-HF, and the pooled…
a multicenter, ambispective cohort study.
In a multicenter ambispective cohort of 3,305 patients with type 2 diabetes and chronic kidney disease, polyethylene glycol-loxenatide demonstrated significant renoprotective effects compared to…
Evidence and Gaps.
The management of chronic coronary syndromes is shifting from an obstructive to a phenotype-guided approach, encompassing INOCA, vasospastic angina, and coronary microvascular dysfunction. While…
Incidence, 30-Day Case Fatality Rates, and Risk Factors Over Time in a Population-Based Study.
A population-based study spanning nearly 30 years reveals that stroke incidence in young adults (20–54 years) has nearly doubled, rising from 33.9 to 62.2 per 100,000 person-years, driven primarily…
balancing euglycaemic ketoacidosis risk and cardiorenal benefits.
This review addresses the perioperative management of SGLT2 inhibitors in patients with heart failure, chronic kidney disease, or type 2 diabetes. While guidelines typically recommend withholding the…
A real-world cohort study of nearly 46,000 patients evaluated whether glucosuria on routine urinalysis serves as a practical proxy for adherence to SGLT2 inhibitors. After inverse probability…
a systematic review.
A systematic review of pooled analyses from the FIDELITY programme demonstrates that finerenone significantly reduces composite renal and cardiovascular outcomes in patients with diabetic kidney…